OptiNose — Technical Presentation (March 2022)
16 slides from OptiNose's technical presentation, Mar 7, 2022
Slide 1: ReOpen1 Clinical Trial Top-Line Results
ReOpen1 Clinical Trial Top-Line Results M a r c h 7 , 2 0 2 2
Slide 2: Forward-Looking Statements
2 Forward-Looking Statements This presentation and our accompanying remarks contain “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements that are not historical facts are hereby identified as forward-looking statements for this
Slide 3: Chronic Sinusitis Overview
optinose_ ——— Chronic Sinusitis Overview
Slide 4: What is Chronic Sinusitis (CS)
4 What is Chronic Sinusitis (CS) CS is an inflammatory disease of the paranasal sinuses that is defined by the presence of at least two out of four cardinal symptoms (i.e., facial pain/pressure, hyposmia/anosmia, nasal drainage, and nasal obstruction) for at least 12 consecutive weeks, in addition t
Slide 5: ReOpen1 A Landmark Phase Trial in the Treatment of Chronic Sinusitis: Design and Top-Line Results
ReOpen1 A Landmark Phase 3 Trial in the Treatment of Chronic Sinusitis: Design and Top-Line Results
Slide 6: ReOpen1 Trial Design Summary
6 EDS Placebo 372 μg Week 24 Double Blinded Phase En d of St ud y ReOpen1 Trial Design Summary Randomized, double-blind, EDS-placebo-controlled, parallel-group, multicenter study to evaluate efficacy and safety of XHANCE 186 μg (1 spray) and 372 μg (2 sprays) BID in subjects with CS (with or without
Slide 7: ReOpen1: Disposition and Baseline Characteristics
7 Re-Open 1: Disposition and Baseline Characteristics EDS Placebo XHANCE 186 mcg XHANCE 372 mcg Subjects Randomized 112 111 109 Subjects Who Completed Study 96 102 101 Subjects Discontinuing Early* 16 9 8 Full Analysis Set 110 110 107 Evaluable subjects with NP 69 69 67 Evaluable subjects without NP
Slide 8: ReOpen-1: Combined Symptom Score Coprimary Endpoint
8 ReOpen-1: Combined Symptom Score Coprimary Endpoint 1 -0.62 -1.58‡ -1.60‡ -2.0 -1.8 -1.6 -1.4 -1.2 -1.0 -0.8 -0.6 -0.4 -0.2 0.0 CS S Po in t R ed uc tio n LS Mean Change in CSS from Baseline to Week 4 EDS-placebo BID OPN-375 186 μg BID OPN-375 372 μg BID BID, twice daily; CSNS, composite symptom n
Slide 9: ReOpen-1: Average Percent Opacified Volume Coprimary Endpoint
9 ReOpen-1: Average Percent Opacified Volume (Ethmoid and Maxillary) Objective CT scan Coprimary Endpoint -1.60 -5.58* -6.20* -7 -6 -5 -4 -3 -2 -1 0 Pe rc en t R ed uc tio n LS Mean Change in APOV of the Ethmoid and Maxillary Sinuses from Baseline to Week 24 EDS-placebo BID OPN-375 186 μg BID OPN-37
Slide 10: Illustration of APOV Improvement (XHANCE 186 µg BID)
10 Illustration of APOV Improvement (Patient Receiving XHANCE 186 µg BID) 6.4% Improvement Week 24Baseline Images reflect individual results and results and may not be representative of results generally.
Slide 11: Illustration of APOV Improvement (XHANCE 372 µg BID)
11 Illustration of APOV Improvement (Patient Receiving XHANCE 372 µg BID) Week 24Baseline 7.0% Improvement Images reflect individual results and results and may not be representative of results generally.
Slide 12: Secondary Endpoints and Subgroup Analysis
12 Secondary Endpoints and Subgroup Analysis Top-line results are limited: full analysis is still ongoing Four defining symptoms of Chronic Sinusitis - XHANCE-treated patients had statistically significant improvement over EDS-placebo treated patients on each of the four symptoms (congestion, rhin
Slide 13: AEs Occurring in ≥3% of Patients and More Common Than Placebo
13 AEs Occurring in ≥3% of Patients and More Common Than Placebo Adverse Event (AE) EDS-placebo BID (N =112) n (%) XHANCE 186 mcg BID (N =111) n (%) XHANCE 372 mcg BID (N =109) n (%) Epistaxis 1 (0.9) 5 (4.5) 13 (11.9) Nasopharyngitis 3 (2.7) 6 (5.4) 3 (2.8) Asthma 1 (0.9) 5 (4.5) 4 (3.7) Nuclear Ca
Slide 14: Closing Remarks
optinose_ ——— Closing Remarks
Slide 15: Additional Phase 3b Clinical Trial Data Expected in Q2 22
15 Additional Phase 3b Clinical Trial Data Expected in Q2 2022 Recruitment Completed July 2021 Recruitment Completed October 2021 Top-line results expected in Q1 2022 Top-line results expected in Q2 2022
Slide 16: ReOpen1 Clinical Trial Top-Line Results
ReOpen1 Clinical Trial Top-Line Results M a r c h 7 , 2 0 2 2